Venn Life Sciences Holdings Plc(“Venn”, “Venn Life Sciences” or the “Company”)Conditional Acquisition of Open Orphan DAC (“Open Orphan”)Suspension of TradingBoard ChangesProposed fundraising 10 May 2019 Venn Life Sciences, an Integrated… read more →
Venn Life Sciences Holdings Plc (“Venn”, “Venn Life Sciences” or the “Company”) Preliminary Final Results for the year ended 31 December 2018 10 May 2019 Venn Life Sciences (AIM: VENN),… read more →
Registration Open for Introduction to Pharmacokinetics Course When: 13th, 14th & 15th, November 2019 Where: Venn Life Sciences, Breda, The Netherlands From April 24 – 26, Venn organized their 3… read more →
An innovative initiative dedicated to start-ups Venn have introduced a new training initiative to help start-ups, at the beginning of their development, to fully benefit from our knowledge and expertise… read more →
On January 28th and 29th, Venn Life Sciences and its partner CEA (Pr. Daniel Gillet’s team) hosted a workshop gathering European experts on Hemolytic Uremic Syndrome caused by Shiga Toxin-producing… read more →